FILING ANALYSIS · THURSDAY, NOVEMBER 5
vTv Therapeutics Inc. VTVT — 8-K: Results of Operations and Financial Condition
neutral
vTv Therapeutics reported completion of enrollment in its Phase 3 CATT1 trial for cadisegliatin, with topline results expected mid 2027, and has a strong balance sheet to fund operations through the data readout. The company also received Orphan Drug Designation for HPPD, its potential treatment for sickle cell disease.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →